Director Ted D. Kellner filed a Statement of Changes in Beneficial Ownership with the SEC on November 20, 2026, reporting the disposition of shares of AIM ImmunoTech Inc. common stock across three indirectly held accounts on November 18, 2026.
Key Highlights
- Reporting person: Ted D. Kellner, identified as a Director of AIM ImmunoTech Inc. (NYSE:AIM)
- Transaction date: All three dispositions occurred on November 18, 2026, at a price of $0.136 per share
- Largest disposition: 14,574 shares disposed through Kelvest I LP, leaving 19,714 shares held indirectly by that entity
- Beta Fund Investment Club: 2,702 shares disposed, with 0 shares remaining in that account following the transaction
- Profit sharing plan: 250 shares disposed through the Kellner, Ted Combined Profit Sharing/Money Purchase Plan, leaving 0 shares in that account
- All transactions coded "D": Each disposition is recorded with transaction code D under Table I - Non-Derivative Securities
- No derivative securities reported: Table II contains no reported derivative security transactions
Kellner's November 18 Dispositions Across Three Indirect Accounts
According to the filing, Ted D. Kellner, a director of AIM ImmunoTech Inc., disposed of a combined 17,526 shares of common stock on November 18, 2026, spread across three separately held indirect accounts. All shares were disposed of at a price of $0.136 per share. The filing was signed by Ted D. Kellner and submitted to the SEC on November 20, 2026.
The filing reports that 14,574 shares were disposed through Kelvest I LP, an entity for which Kellner serves as Manager of T&M Partners LLC, the General Partner of Kelvest I LP. Following that transaction, 19,714 shares remain indirectly held through Kelvest I LP, according to the filing. An additional 2,702 shares were disposed through the Beta Fund Investment Club, where Kellner serves as manager and is an investor; the filing notes that he "disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein." A further 250 shares were disposed through the Kellner, Ted Combined Profit Sharing/Money Purchase Plan, for which he serves as trustee. Both the Beta Fund Investment Club account and the profit sharing plan account show zero remaining shares following the reported transactions.
AIM ImmunoTech Inc. is listed on the NYSE under the ticker symbol AIM. The filing covers only non-derivative securities; no entries appear in Table II, which addresses derivative instruments such as options, warrants, or convertible securities. The filing was made individually by one reporting person and is not marked as an amendment to a prior filing.
What Was Disclosed
Director Ted D. Kellner reported the disposal of 17,526 shares of AIM ImmunoTech Inc. common stock on November 18, 2026, at $0.136 per share, spread across three indirectly held vehicles, with 19,714 shares remaining in the Kelvest I LP account.


Please wait processing your request...